**2**002

PTO/SB/§1 (11-04) Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons ar

## **POWER OF ATTORNEY** and **CORRESPONDENCE ADDRESS** INDICATION FORM

Attorney Docket Number	P-088-R				
Examiner Name	RUSSEL, Jeffrey E.				
Art Unit	1654				
Title	Glycopeptide Phosphonate Derivatives				
First Named Inventor	LEADBETTER et al.				
Filing Date	May 1, 2001				
Application Number	09/847,042, now USPN 6,635,618 B2				
e regained to reaporto to a collection of t	filottiation unless it displays a valid OMB conedi fluttiper.				

I hereby revoke all previous powers of attorney given in the above-identified application.									
I hereby a	ppoint:		<u> </u>						
☑ Practition	☑ Practitioners associated with the Customer Number:			27038					
OR									
Practitioner(s) named below:									
	<del></del>	Name	<del></del>	Registration Number					
-									
		· · · · · · · · · · · · · · · · · · ·				···. •	<u> </u>	!	
	<del></del>			<del></del>					
Ĺ	<del> </del>			······································				]	
as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.									d States
Please recognize or change the correspondence address for the above-identified application to:									
The address associated with the above-mentioned Customer Number								•	
OR  The address associated with Customer Number:									
OR									
Firm or	al Name								
Address									
City			State			ZIP			
Country									
Telephone			Fax						
I am the:									
Applicant/Inventor.									
Assignee of record of the entire Interest. See 37 CFR 3.71.									
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)									
		SIGNATURE of Applic	ant or As	signee o	f-Reco	ord	7		
Signature		AU HOURS		$\mathcal{L}$	Date		April 12	2005	
Name	4	effre A. Hagenah, Reg. No. 35,175	<u>د</u>	Telephone (650) 808-6406					: •
Title and Company Assistant Secretary of Theravance, Inc.									
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.									orms if
*Total of forms are submitted.								i	

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual) case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**2003** 

APR 1 2 2005

PTO/SB/96 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent end Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB centrol number.

STATEMENT UNDER 37 CFR 3.73(b)					
Applicant/Patent Owner: LEADBETTER et al.					
Application No./Patent No.: US 6,635,618 (09/847,042 Filed/Issue Date: October 21, 2003					
Entitled: Glycopeptide Phosphonate Derivatives					
Theravance, Inc. , a corporation (Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government ag	ency, etc.)				
states that it is:  1.   the assignee of the entire right, title, and interest; or					
2. an assignee of less than the entire right, title and interest.  The extent (by percentage) of its ownership interest is %					
in the patent application/patent identified above by virtue of either:					
An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recein the United States Patent and Trademark Office at Reel, Frame, or for which a continuous statement is attached.  OR  B. A chain of title from the Inventor(s), of the patent application/patent identified above, to the current assignee as below:	сору				
1. From: Inventors To: Advanced Medicine, Inc. (Assignment document) The document was recorded in the United States Patent and Trademark Office at Reel 012049 Frame 0333 , or for which a copy thereof is attached.					
From: _Advanced Medicine, Inc	,				
3. From:					
Additional documents in the chain of title are listed on a supplemental sheet.  Copies of assignments or other documents in the chain of title are attached.  [NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTC MPEP 302.08]					
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.  April 2:2005  Signature Date  Jeffrey A. Hagenah, Reg. No. 35,175  (650) 808-6406					
Printed or Typed Name Telephone Num					
Assistant Secretary of Thervance, Inc.					

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form ant/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.